FDA Clears Laser for Tennis Elbow: A New Light on Pain Management?

SOLON, OH – June 09, 2026 – In a world saturated with promises of quick fixes for chronic pain, the U.S. Food and Drug Administration has given a nod to a technology that banks not on promises, but on peer-reviewed proof. Multi Radiance Medical (MRM), a key player in therapeutic laser technology, has secured FDA 510(k) clearance for its MR5 ACTIV PRO device to treat lateral epicondylitis, the debilitating condition better known as 'tennis elbow'.

This isn't just another gadget for the physical therapist's office. The clearance signals a potential shift in how clinicians approach one of the most common causes of elbow pain, a condition affecting an estimated 10.5 million adults globally each year. While the 'tennis' moniker suggests a sports injury, the reality is that it more frequently impacts working-age adults engaged in repetitive daily and occupational tasks, eroding grip strength, productivity, and overall quality of life. For them, this new, non-invasive, drug-free option represents a beacon of hope. But as with any technological advance in healthcare, the actionable intelligence lies beyond the headline, in the rigor of the science and the practical realities of cost and access.

The Gold Standard of Evidence

In the often-murky waters of medical device marketing, claims of efficacy can be difficult to substantiate. Multi Radiance Medical has addressed this head-on by subjecting its technology to the highest level of scientific scrutiny: a prospective, randomized, triple-blind, placebo-controlled, multi-center clinical study. The results, which formed the basis of the FDA submission, were also published in the prestigious peer-reviewed journal BMJ Open, making the data transparently available to the global medical community.

"High-quality clinical research remains essential for advancing evidence-based healthcare," stated Dr. Ernesto Cesar Pinto Leal Junior, the study's principal investigator. "Randomized, triple-blind, placebo-controlled studies provide the highest level of clinical evidence and help ensure that healthcare professionals can make treatment decisions with confidence."

The trial's design is its strength. 'Triple-blind' means that the patients, the clinicians administering the treatment, and the researchers analyzing the data were all unaware of who received the active laser therapy versus the placebo. This methodology is critical for eliminating bias. The study met its primary goal, demonstrating that 72% of subjects receiving the active laser treatment achieved clinical success—defined as at least a 30% reduction in pain—compared to just 40% in the placebo group. The statistical significance (p=0.045) confirms the outcome was unlikely due to chance. Furthermore, the study noted a significant decrease in serum tumor necrosis factor-alpha (TNF-α), a key inflammatory marker, in the active treatment group, suggesting the therapy works by modulating biological pathways at a cellular level.

The technology itself, known as photobiomodulation (PBM), uses specific wavelengths of light to stimulate tissue repair and reduce pain and inflammation. The MR5 ACTIV PRO employs a proprietary combination of a 905 nm Super Pulsed Laser, 850 nm infrared light, and 660 nm red light. This multi-wavelength approach is designed to deliver energy deep into the tissue safely, triggering cellular processes that can accelerate healing.

"At Multi Radiance Medical, our objective is not simply to develop technology, but to validate its clinical application through rigorous scientific investigation," said Douglas Johnson, the company's Chief Science Officer. This commitment to validation provides a level of assurance that is often missing, giving clinicians a solid foundation upon which to base their treatment protocols.

A Crowded Field: Expanding the Clinician's Toolkit

The FDA clearance positions the MR5 ACTIV PRO within a large and growing market for lateral epicondylitis treatment, projected to exceed $2.5 billion within the next decade. Currently, the landscape is dominated by non-surgical options, reflecting a strong patient and provider preference for avoiding the risks and recovery time associated with invasive procedures.

Clinicians' existing toolkits include rest, bracing, physical therapy exercises, and anti-inflammatory drugs (NSAIDs). For more persistent cases, corticosteroid injections have long been a common practice, though their long-term efficacy and potential for tissue damage are subjects of ongoing debate. Newer options like Platelet-Rich Plasma (PRP) injections and Extracorporeal Shockwave Therapy (ESWT) have also gained traction, but often with mixed results and high out-of-pocket costs.

This is the environment into which Multi Radiance Medical's laser enters—not as a replacement for all other therapies, but as a potent, evidence-based addition. The FDA clearance is for "adjunctive use," meaning it is designed to be integrated into a comprehensive treatment plan alongside other modalities like physical therapy. This aligns with modern pain management philosophy, which increasingly favors a multi-modal approach over reliance on a single intervention.

"This FDA clearance represents another important milestone for Multi Radiance Medical and reflects our longstanding commitment to building our business on science, clinical evidence, and regulatory rigor," said Max Kanarsky, President and CEO. He emphasized that the clearance "provides healthcare professionals with an evidence-based, non-invasive, drug-free treatment option for patients suffering from musculoskeletal pain."

The Hidden Costs of Innovation: Access and Affordability

While the science is compelling, the path from FDA clearance to widespread patient benefit is paved with practical and economic hurdles. This is the hidden cost of progress. The MR5 ACTIV PRO is a professional medical device, and its acquisition represents a significant capital investment for clinics, with prices for similar advanced laser systems ranging from approximately $10,000 to $16,000.

This initial cost inevitably influences the price of treatment for patients. More critically, it raises the question of insurance reimbursement. While the photobiomodulation market has seen increasingly favorable reimbursement policies, coverage for specific treatments remains highly variable among insurance providers. Patients may find that this validated, drug-free therapy is considered experimental by their insurer, leaving them to bear the full cost out-of-pocket. This creates a potential two-tiered system of access, where those with the ability to pay privately can benefit from the latest technology while others are left with older, less effective, or more invasive options.

Furthermore, the device's designation for adjunctive use means patients will be incurring costs not just for the laser sessions but for the full suite of care prescribed by their physical therapist or physician. While this comprehensive approach is clinically sound, it adds layers of complexity and expense that must be navigated.

The challenge for Multi Radiance Medical and the healthcare system at large will be to bridge this gap between clinical validation and equitable access. As photobiomodulation continues to build a robust evidence base, the pressure will mount on payers to recognize its value and provide consistent coverage. For now, patients and clinicians must weigh the demonstrated benefits of this powerful technology against the very real barriers of cost and system-level adoption.